Rheumatological paraneoplastic syndrome in lung cancer

Syniachenko O.V.¹, Dumanskiy Yu.V.¹, Stoliarova O.Yu.², Stepko P.A.¹

• ¹Донецкий национальный медицинский университет, Лиман
• ²Национальный институт рака, Киев

Summary. The purpose of the investigation was to study the prevalence of rheumatological paraneoplastic syndrome (RPS) lung cancer (LС) and the nature of its individual manifestations in diffe­rent variants of LС development. 1071 patients with LC at the age from 24 to 86 years (on the average, 59 years) were examined, among which 83% of men and 17% of women. Small cell histological variant of the disease was detected in 18% of cases, and not small cell — in 82%, ratio IA–IB, IIA–IIB, IIIA, IIIB and IV stages of the disease was 1:2:23:35:36. The defeat of the upper lobes of the lung was established in 27% of cases, the lower lobes in 15%, the uppermost localization on the left in 19%, the uppermost in 25%, the middle one at 1%, and the middle lobe — 4%), the mediastinal variant of the disease took place in 9% of the examined one. 79% of the examined had a central form of LC, 21% had peripheral. In 18% of cases with LC, 20 variants of rheumatological RPSLC (from one to eight per patient) are diagnosed, which is more common for women and has gender specific prevalence (polymyositis, leukocytoclastic vasculitis, panniculitis or nodal erythema), depends on the localization of the tumor process, Mediastinal), stage, severity of the course and histological variant of neoplasm (rheumatoid-like arthritis, osteoarthropathy, palmar fasciitis, Dupuytren’s contractures, tendovaginitis, dermatopolymiositis, inflammation of the peripheral nervous system, development of ophthalmopathy and gynecomastia), and the risk factors for RPSLC at LC are the presence of exudative pleurisy, compression of the inferior vena cava, lymphadenopathy, Germination of the tumor in the chest wall and mediastinum. The obtained data will be useful for the development of medical technology for early diagnosis of radar, surgical, radiation and medicinal treatment of the disease and for monitoring the effectiveness of the measures taken, as well as pathogenetic therapy of RPSLC.